Search

The article reports on the World Health Organization (WHO)-recommended strategy on screening all individuals for Ebola virus disease (Ebola) when entering and exiting airports in West Africa (WA). Topics covered include implementation of the procedure in August 2014 by WA health ministries with global partners such as the U.S. Centers for Disease Control and Prevention (CDC). Also mentioned most Ebola affected WA countries including Guinea, Liberia and Sierra Leone.

Recent manufacturing problems resulted in a shortage of the only U.S.-licensed yellow fever vaccine. This shortage is expected to lead to a complete depletion of yellow fever vaccine available for the immunization of U.S. travelers by mid-2017. CDC, the Food and Drug Administration (FDA), and Sanofi Pasteur are collaborating to ensure a continuous yellow fever vaccine supply in the United States. As part of this collaboration, Sanofi Pasteur submitted an expanded access investigational new drug (eIND) application to FDA in September 2016 to allow for the importation and use of an alternative yellow fever vaccine manufactured by Sanofi Pasteur France, with safety and efficacy comparable to the U.S.-licensed vaccine; the eIND was accepted by FDA in October 2016. The implementation of this eIND protocol included developing a systematic process for selecting a limited number of clinic sites to provide the vaccine. CDC and Sanofi Pasteur will continue to communicate with the public and other stakeholders, and CDC will provide a list of locations that will be administering the replacement vaccine at a later date. [ABSTRACT FROM AUTHOR]